New data show that routine administration of alvimopan could be a financially viable option for preventing postoperative ileus in patients undergoing radical cystectomy. Hilton et al. performed decision-tree model analysis of healthcare costs and outcome probabilities, and concluded that routine use of alvimopan could reduce costs—assuming that postoperative ileus extends hospital stay by ≥3.5 days and occurs in ≥14% of patients, and alvimopan reduces the risk of postoperative ileus by ≥44%.